- Trial phase
- Approved
- Time to market
- Already approved and commercially available since October 2017.
Yescarta has no scheduled PDUFA date or pivotal readout in the next 12 months. The next catalyst to watch is the Q4 2026 earnings release (late January/early February 2027) for the sales trajectory and any commentary on competitive dynamics versus Breyanzi and Carvykti. Longer term, watch for any data from Kite's next-generation CAR-T programs or label expansion studies that could reverse the sales decline.
Price Chart
Executive Summary
Yescarta (axicabtagene ciloleucel) is a CD19-directed CAR-T cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences (GILD). First approved by the FDA in October 2017 for relapsed/refractory large B-cell lymphoma, it now carries multiple approved indications including second-line LBCL (ZUMA-7, 2022), follicular lymphoma (ZUMA-5, 2021), and a February 2026 label update removing limitations of use for primary CNS lymphoma. Yescarta is a mature, marketed product facing intensifying competition from Bristol Myers Squibb's Breyanzi, Novartis' Kymriah, Johnson & Johnson's Carvykti, and others. Sales are in decline: Q3 2026 revenue was $294 million, down 16% year-over-year, and full-year 2025 sales were approximately $1.5 billion. For Gilead, a $165 billion diversified biopharma, Yescarta is a meaningful but not dominant revenue contributor, with no upcoming binary regulatory catalyst on the horizon.
How It Works
Yescarta is a personalized cancer immunotherapy. A patient's own immune cells (T cells) are collected, genetically modified in a lab to recognize and attack cancer cells that carry a protein called CD19, and then infused back into the patient. This is known as CAR-T cell therapy. It is a one-time treatment designed to train the immune system to fight certain types of blood cancers (lymphomas).
Trial Status
Yescarta is FDA-approved across multiple indications based on the ZUMA-1 (third-line LBCL, 2017), ZUMA-5 (follicular lymphoma, 2021), and ZUMA-7 (second-line LBCL, 2022) trials. The ZUMA-7 study demonstrated a statistically significant overall survival benefit versus standard of care, with 5-year follow-up data published in the New England Journal of Medicine. A February 2026 label update removed previous limitations of use for relapsed/refractory primary CNS lymphoma based on safety data. Ongoing analyses include real-world evidence and combination studies.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates or pivotal readouts identified for Yescarta in the next 12 months.
- Q4 2026 / full-year 2026 earnings release (late January/early February 2027) will provide updated sales trajectory and competitive commentary.
- ASH or other medical conference data presentations on real-world evidence or long-term follow-up from ZUMA-7.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GILEAD SCIENCES, INC. 8-K GILD ·Originating report